Here, we evaluated baseline and on-treatment expression of BCL2, BCL2L1 (encoding BCL-xL), and MCL1 in 19 myelofibrosis patients receiving ruxolitinib. This evidence concerns the gene BCL2L1 and myelofibrosis.